RP

Ruby Pandey

Active Director Director DIN 06961002
DIN 06961002 First appointment Jan 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2020
Shareholding value •••• Premium profile

About Ruby Pandey

Data last updated:

Ruby Pandey is a Director at Aimcad Biotech Private Limited (since 2020). The company operates in Pharma. Aimcad Biotech Private Limited reported revenue of ₹4.69 Cr (FY 2024).

DIN 06961002
Primary Designation Director
Industry Pharma
First Appointment 25 Jan 2020
Oldest Company Age 13 yrs
Largest company Aimcad Biotech Private Limited · ₹4.69 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aimcad Biotech Private Limited U74120MH2013PTC272456
Director25 Jan 20202013₹4.69 Cr (FY 2024)Active

Board colleagues of Ruby Pandey

Directorship timeline

Open interactive timeline →
Aimcad Biotech Private Limited
Premium access

Shareholding and investment profile for Ruby Pandey

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ruby Pandey

Ruby Pandey currently holds 1 directorship: Aimcad Biotech Private Limited (Director, since 25 Jan 2020, revenue ₹4.69 Cr (FY 2024)).

Ruby Pandey was first appointed on 25 Jan 2020 as Director at Aimcad Biotech Private Limited.

The current boards of Ruby Pandey's companies include Priyanka Keshari (Aimcad Biotech Private Limited), Ravi Kumar Pandey (Aimcad Biotech Private Limited), Shyam Kumar Keshari (Aimcad Biotech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available